Keyphrases
Monotherapy
100%
Inception Cohort Study
98%
Comparative Effectiveness
93%
Primary Prevention
83%
Cardiovascular Prevention
67%
Antihyperlipidemic
62%
Beta-blockers
62%
Confidence Interval
61%
Drug Therapy
54%
Cardiac Drugs
50%
Thiazides
50%
Netherlands
37%
Risk Factors
37%
Angiotensin Receptor Blockers
33%
Cardiovascular Medications
31%
Medication Adherence
31%
Simvastatin
31%
Hazard Ratio
31%
Calcium Channel Blockers
31%
Population-based
31%
Disease Incidence
31%
Temporal Trends
31%
Global Distribution
31%
Chronic Obstructive Pulmonary Disease
31%
Distribution Risk
31%
Ecological Analysis
31%
Disease-specific Mortality
31%
Inverse Probability
19%
Angiotensin-converting Enzyme Inhibitor (ACEi)
15%
Groningen
14%
Follow-up Time
14%
Antihypertensive Therapy
12%
Non-adherence
12%
Diabetes Drugs
11%
Cardiovascular Events
11%
Major Adverse Cardiovascular Events
10%
Patient-independent
10%
Cardiovascular Risk
10%
Atorvastatin
10%
Cox Regression
10%
Antihypertensive Drugs
10%
Pharmacy
9%
Cardiovascular Disease Events
9%
Prescription Database
9%
Incidence Rate
8%
Cardiovascular Disease
7%
ACE Inhibitors
7%
Cardiovascular Therapy
6%
Mixed Models
6%
Claims Database
6%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Cohort Study
98%
Antihypertensive Agent
96%
Antilipemic Agent
78%
Beta Adrenergic Receptor Blocking Agent
62%
Pharmacotherapy
59%
Cardiac Agent
50%
Thiazide Diuretic Agent
50%
Angiotensin Receptor Antagonist
33%
Cardiovascular Disease
31%
Simvastatin
31%
Calcium Channel Blocker
31%
Nitric Acid Derivative
31%
Antithrombocytic Agent
31%
Antivitamin K
31%
Dipeptidyl Carboxypeptidase Inhibitor
23%
Cardiovascular Disease
20%
Chronic Obstructive Lung Disease
20%
Asthma
20%
Hyperlipidemia
15%
Drug Dispensing
15%
Diseases
15%
Prevalence
15%
Antihypertensive Therapy
12%
Pravastatin
10%
Population Study
6%
Rheumatoid Arthritis
5%
Fluindostatin
5%
Fibric Acid Derivative
5%
Diabetes Mellitus
5%
Rosuvastatin
5%
Effectiveness Study
5%
Drug Action
5%
Inflammatory Arthritis
5%